Protocol Details

Cholinergic Modulation of Cognition and Emotion in Mood Disorders: Functional Neuroimaging Studies

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number	03-M-0108
Sponsoring Institute	National Institute of Mental Health (NIMH)
Recruitment Detail	Type: Participants currently recruited/enrolled Gender: Male & Female Min Age: 18 Max Age: 55
Referral Letter Required	No
Population Exclusion(s)	Children
Special Instructions	Currently Not Provided
Keywords	Scopolamine; Depression; fMRI; Cognition; Emotion; Brain
Recruitment Keyword(s)	Bipolar Disorder; Depression; Major Depressive Disorder; MDD; Healthy Volunteer; HV
Condition(s)	Mood Disorders; Healthy; Unipolar Depression; Bipolar Depression
Investigational Drug(s)	Scopolamine Nasal Spray
Investigational Device(s)	None
Intervention(s)	Drug: Transderm Scopolamine
Supporting Site	National Institute of Mental Health

This study looks at the role of a specific brain chemical system in the mood and attention symptoms seen in major depression and bipolar disorders using functional brain imaging.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

Three groups of right-handed subjects will be recruited for studies under this protocol: unipolar depressives, bipolar depressives and age matched healthy controls. Subjects with both unipolar and bipolar depression appear to exhibit abnormal cholinergic function during the depressed phase (see above), and no differences are hypothesized to exist between MDD and BD depressives herein. However, while BD subjects are more difficult to recruit, the evidence for cholinergic abnormalities has been particularly compelling for BD. Therefore both groups will be recruited.

The presence of inclusion and exclusion criteria will be established using both an unstructured clinical interview with a psychiatrist and the Structured Clinical Interview for DSM-IV (SCID). Family history of mental illness will be obtained from the subject using the Family Interview of Genetic Studies. We will recruit 15 subjects per group per study, including the dose finding study for a total of 90 subjects per group.

Depressed Samples:

Subjects (ages 18-45) currently suffering from a major depressive episode falling into one of the following subgroups:

1). Major Depressive Disorder (MDD): Subjects will be selected, with primary MDD currently depressed as defined by DSM-IV criteria for recurrent MDD and current IDS score in the moderately-to-severely depressed range.

2). Bipolar Disorder (BD); Subjects will be selected who meet DSM-IV criteria for bipolar disorder and are currently depressed, with IDS score in the moderately-to-severely depressed range.

Healthy Control Sample:

Subjects (ages 18-45) who have not met criteria for any major psychiatric disorder and have no known first-degree relatives with MDD or BD will be selected. Control subjects will be matched to depressed subject for age, gender and education.

EXCLUSION CRITERIA:

Subjects will be recruited who are drug-naive or who have not received psychotropic drugs for at least 3 weeks (8 weeks for fluoxetine).

Subjects will also be excluded if they have:

a) serious suicidal ideation or behavior, or current delusions or hallucinations,

b) inability to provide informed consent,

c) medical or neurological illnesses likely to affect physiology or anatomy,

d) a history of drug or alcohol abuse within 1 year or a lifetime history of alcohol or drug dependence (DSM IV criteria),

e) current or past history of other axis I disorders that preceded the onset of MDD or BD,

f) current pregnancy (documented by pregnancy testing prior to scanning),

g) current breast feeding,

h) general MRI exclusion criteria (including the presence of pacemakers, cochlear implants, surgical clips or metal fragments in their eyes or body parts),

i) vision and/or hearing problems severe enough to interfere with testing,

j) electrocardiographic evidence of ischemia, arrhythmia, conduction defect, or myocardial infarction,

k) current blood pressure of greater than 140 mm Hg or less than 90 mm Hg systolic, or greater than 90 mm Hg diastolic (due to the potential cardiovascular effects of scopolamine and physostigmine),

l) clinically significant cerebrovascular or cardiovascular disease, hypertension, congestive heart disease, angina pectoris, advanced arteriosclerosis, gross neurological impairment, hyperthyroidism, known hypersensitivity or idiosyncracy to anticholinergic agents, glaucoma, renal or hepatic impairment,

m) current nicotine use (due to the effects of nicotine on the cholinergic system),

n) narrow angle glaucoma (due to the possibility of exacerbation of this condition by scopolamine),

o) age greater than 45 years (to reduce the biological heterogeneity encompassed by the MDD and BD criteria, since subjects with a late age-at onset for depression have a far greater likelihood of having MRI correlates of cerebrovascular disease than age-matched, healthy controls or age-matched, early-onset depressives),

p) exposure within two weeks to medications likely to effect cerebral blood flow and metabolism or likely to interact with anti-cholinergic medications (e.g. narcotics or anti-cholinergic agents)- as verified by history and urine drug screen,

q) HIV positive status.

--Back to Top--

Citations:

Elliott R, Rubinsztein JS, Sahakian BJ, Dolan RJ. Selective attention to emotional stimuli in a verbal go/no-go task: an fMRI study. Neuroreport. 2000 Jun 5;11(8):1739-44.

Murphy FC, Sahakian BJ, Rubinsztein JS, Michael A, Rogers RD, Robbins TW, Paykel ES. Emotional bias and inhibitory control processes in mania and depression. Psychol Med. 1999 Nov;29(6):1307-21.

Murray LA, Whitehouse WG, Alloy LB. Mood congruence and depressive deficits in memory: a forced-recall analysis. Memory. 1999 Mar;7(2):175-96.

--Back to Top--

Contacts:

Principal Investigator	Referral Contact	For more information http://clinicalstudies.info.nih.gov.
Maura L. Furey, Ph.D. National Institute of Mental Health (NIMH) National Institutes of Health Building 15K Room 113 1K North Drive Bethesda, Maryland 20892 (301) 594-2894 grillonc@mail.nih.gov	Maura L. Furey, Ph.D. National Institute of Mental Health (NIMH) National Institutes of Health Building 15K Room 113 1K North Drive Bethesda, Maryland 20892 (301) 594-2894 grillonc@mail.nih.gov	Patient Recruitment and Public Liaison Office Building 61 10 Cloister Court Bethesda, Maryland 20892-4754 Toll Free: 1-800-411-1222 TTY: 301-594-9774 (local),1-866-411-1010 (toll free) Fax: 301-480-9793 prpl@mail.cc.nih.gov

Clinical Trials Number:

NCT00055575

--Back to Top--

QUESTIONS?

Contact the Patient Recruitment and Public Liaison Office for:

• Details on how to participate in a study
• Details on how to refer a patient to a study

NIH Clinical Studies Information Request

---

Contact the Office of Communications for:

• General information about the NIH Clinical Center

www.cc.nih.gov/contact.shtml

---

Contact the Department Clinical Research Informatics, (DCRI) for:

• Technical questions about Adobe Acrobat and the PDF format
• Technical questions about this web server

webmaster@cc.nih.gov